Request Demo

Last update 25 Apr 2025

Cetirizine Hydrochloride

Last update 25 Apr 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryCetirizine hydrochloride, a minuscule molecule drug, operates as an H1 receptor antagonist by targeting the H1 receptor. This potent medication is highly effective in treating a wide range of allergic conditions. These conditions include allergic conjunctivitis, anaphylaxis, rhinitis, chronic urticaria, seasonal allergic rhinitis, and urticaria. Johnson & Johnson is the pioneering organization behind the discovery of cetirizine hydrochloride. Medical approval for this remarkable drug was granted in 1991. Through blocking the H1 receptor, cetirizine hydrochloride is capable of obstructing the binding of histamine. Histamine is the prime cause of various allergic reaction symptoms. Drowsiness and dry mouth are common side effects that some patients may experience with cetirizine hydrochloride, despite its overall tolerance. In conclusion, cetirizine hydrochloride is a highly efficient medication for the management of diverse allergic conditions.

Drug Type

Small molecule drug

Synonyms

Cetirizien Hydrochloride Drops, Cetirizine, Cetirizine Dihydrochloride

+ [46]

Target

H1 receptor

Action

antagonists

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesEye Diseases+ [3]

Active Indication

Rhinitis, Allergic, SeasonalConjunctivitis, AllergicDermatitis+ [8]

Inactive Indication

Acute conjunctivitisChronic UrticariaDermatitis, Atopic+ [3]

Originator Organization

Johnson & Johnson

Active Organization

Teva UK Ltd.Pfizer Canada ULC

UCB Japan Co. Ltd.

+ [7]

Inactive Organization

McNeil AB

Nicox Ophthalmics, Inc.

GSK Plc

+ [8]

Drug Highest PhaseApproved

First Approval Date

Canada (31 Dec 1991),

Rhinitis, AllergicUrticaria

RegulationPriority Review (China)

Structure/Sequence

Molecular FormulaC21H26Cl2N2O3

InChIKeyCUSPGNDCPOVPBA-UHFFFAOYSA-N

CAS Registry83881-52-1

118

Clinical Trials associated with Cetirizine Hydrochloride

NCT06890260

/ RecruitingNot ApplicableIIT

A Clinical Randomized Controlled Study of Electroacupuncture Combined With Microneedle Knife in the Treatment of Moderate to Severe Allergic Rhinitis

Based on the inclusion and exclusion criteria, patients with allergic rhinitis who meet the requirements are selected as trial subjects, and the efficacy is clarified in a randomized controlled design trial. We will Use the total nasal symptom score as the primary outcome index, serum chemokine, intercellular adhesion molecule-1, eosinophil cationic protein, total non-nasal symptom score, and rhinitis-related quality of life scale as secondary outcome indexes, and oral cetirizine hydrochloride tablets and nasal budesonide spray as the control group, the efficacy of the subjects in the electroacupuncture combined with microneedle knife group and the drug group will be observed respectively before treatment, after 2 weeks of treatment, after 4 weeks, 1 month follow-up after the end of treatment, and 3 months follow-up after the end of treatment. 4 weeks later, 1 month follow-up after the end of treatment and 3 months follow-up after the end of treatment.

Start Date11 Apr 2025

Sponsor / Collaborator

Zhejiang Hospital

CTRI/2024/08/072453

/ RecruitingPhase 3

A Prospective, Randomized, Double-blinded, Multi-centric, Two-arm, Parallel-group, Active-Controlled, Phase III Study to Assess the Efficacyand Safety of Cetirizine Ophthalmic in Patients having ocular itching associated with allergic conjunctivitis - NIL

Start Date20 Aug 2024

Sponsor / Collaborator

Akums Drugs & Pharmaceuticals Ltd.

[+1]

CTR20233269

/ RecruitingPhase 3

盐酸西替利嗪注射液治疗急性荨麻疹的有效性和安全性的随机、双盲、阳性对照、多中心III期临床研究

[Translation] A randomized, double-blind, positive-controlled, multicenter phase III clinical study on the efficacy and safety of cetirizine hydrochloride injection in the treatment of acute urticaria

评价盐酸西替利嗪注射液治疗急性荨麻疹的有效性和安全性

[Translation]

To evaluate the efficacy and safety of cetirizine hydrochloride injection in the treatment of acute urticaria

Start Date22 Apr 2024

Sponsor / Collaborator

Shandong New Time Pharmaceutical Co. Ltd.

100 Clinical Results associated with Cetirizine Hydrochloride

100 Translational Medicine associated with Cetirizine Hydrochloride

100 Patents (Medical) associated with Cetirizine Hydrochloride

3,695

Literatures (Medical) associated with Cetirizine Hydrochloride

01 Jun 2025·JOURNAL OF HYDROLOGY

A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment

Author: Slosarczyk, Kinga ; Dabrowska, Dominika

The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.

01 May 2025·JOURNAL OF HAZARDOUS MATERIALS

Predicting sorption of diverse organic compounds in soil-water systems: Meta-analysis, machine learning modeling, and global soil mapping

Article

Author: Zhang, Kai ; Sun, Jiachun ; Zhang, Huichun

In recent decades, the environmental detection of various organic compounds (OCs) has highlighted the limitations of conventional soil-water sorption models, which simplify complex experimental conditions and often overlook OCs with polyfunctional and ionizable structures. To address these shortcomings, we compiled a comprehensive soil-water sorption dataset encompassing 20,945 data points for 419 OCs with various functional groups and 1037 different soils. Meta-analysis of the dataset revealed the trends of soil sorption associated with OC substructures, soil properties, and solution conditions. Machine learning models employing the XGBoost algorithm, in conjunction with MACCS fingerprints and experimental conditions, were developed to cover the entire spectrum of speciation for cationic, neutral, and anionic species. Among these, the individual models tailored to each speciation achieved an overall root-mean-square-error value of 0.32 for log K_d. Model interpretation revealed that the models correctly understood the contributions of various substructures, such as multiple aromatic rings and nitrogen or oxygen atoms, to sorption. The models were also found to accurately capture isotherm nonlinearity and the pH effect on the sorption of ionizable OCs. Finally, utilizing soil properties from the Harmonized World Soil Database, the models predicted the sorption of diverse OCs based on global soil properties under simulated environmental scenarios.

01 Apr 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Using artificial neural networks to elucidate retention interactions on stationary phases with amine moieties dedicated to supercritical fluid chromatography

Author: Plachka, Katerina ; Gazarkova, Tatana ; Pilarova, Veronika ; Plachká, Kateřina ; Nováková, Lucie ; Pilařová, Veronika ; Svec, Frantisek ; Švec, František ; Garrigues, Jean-Christophe ; Novakova, Lucie ; Gazárková, Taťána

The retention mechanisms of small mols. on a wide range of stationary phases using different mobile phase compositions are one of the most discussed topics in current state-of-the-art supercritical fluid chromatog. (SFC).Although various theories have been published on retention behavior, prediction, and stability over time, an in-depth insight into the mechanisms is still lacking.Our study focused on the description of the retention mechanisms on columns with amine moieties, i.e., 2-ethylpyridine, 2-picolylamine, 1-aminoanthracene, and diethylamine, dedicated to SFC, using three different compositions of organic modifier, i.e., methanol, methanol + 10 mmol/L NH₃, and methanol + 2% H₂O, in CO₂.An extensive set of analytes characterized by more than 200 mol. descriptors was used.The importance of the effect of each mol. descriptor on the retention behavior was determined by artificial neural networks.Thus, the descriptors increasing and/or decreasing retention on individual columns using different mobile phase compositions were defined.The data collected over one year of column use were statistically evaluated to describe the retention behavior of small mols. on the tested stationary phases using three organic modifiers and to describe the changes in retention behavior over time.As the development of the SFC method can be laborious and time-consuming, this publication offers a detailed description of the interactions taking place between the analyte and the SFC stationary phase.Understanding these fundamental processes will enable faster development of SFC methods using quality-by-design principles.

112

News (Medical) associated with Cetirizine Hydrochloride

19 Mar 2025

·www.globenewswire.com

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also completed their last visit and results remain on track for Q3 2025 March 19, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient completed their final visit in the Whistler Phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in intraocular pressure (IOP) lowering. The Whistler Phase 3b trial enrolled 18 healthy volunteers with ocular hypertension in a double-masked, placebo-controlled study investigating the action of NCX 470 on aqueous humor parameters including trabecular meshwork outflow and episcleral venous pressure. Each subject participated in the trial for approximately 8 days.About NCX 470NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the two Phase 3 clinical trials, have been extensively published and are available on our website. The second Phase 3 clinical trial, Denali, is currently ongoing. The last American patient in Denali has completed their final visit, with Chinese patients completing theirs, and the results are expected in Q3 2025. Mont Blanc and Denali have been designed to fulfill the regulatory requirements for safety and efficacy Phase 3 trials to support NDA submissions in both the U.S. and in China, where NCX 470 is exclusively licensed to Ocumension Therapeutics. NCX 470 is also licensed exclusively to Kowa for Japan. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” and in section 4 of the “Rapport semestriel financier et d’activité 2024” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_WhistlerLPLV_19March2025_PR_FINAL

Phase 3

28 Jan 2025

·www.globenewswire.com

Nicox Announces Scientific Presentation and Conference Attendance in H1 2025

Press Release Nicox Announces Scientific Presentation and Conference Attendance in H1 2025January 28, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced a presentation at the upcoming American Glaucoma Society (AGS) Annual Meeting 2025 and participation in a number of key ophthalmology and financial conferences in the first half of 2025. Presentation of additional analysis of the NCX 470 Mont Blanc Phase 3 Clinical trial AGS 2025 Annual Meeting – February 26 to March 2, 2025, Washington, U.S. Poster Title: Diurnal Intraocular Pressure Control Responder Analysis with NCX 470 Versus Latanoprost in the Phase 3 MONT BLANC TrialType: Poster Presentation Session Date: Saturday March 1, 2025 from 7:00 am to 8:00 am (local time). Presenter: Dr. Robert Fechtner, Chair of the Department of Ophthalmology at SUNY Upstate Medical University in Syracuse, NY Upcoming Conference Attendance Allinvest securities Biomed Forum – February 4, 2025 – Paris, France Investor Access – April 1-2, 2025 – Paris, France Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting – May 4-8, 2025 – Salt Lake City, Utah, U.S.BIO International Convention – June 16-19, 2025 – Boston, MA, U.S. Members of the management team will be available for one-on-one meetings at these events. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.com Analyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” and in section 4 of the “Rapport semestriel financier et d’activité 2024” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_H1_2025_CONFERENCES_PR_FINAL

Phase 3

21 Jan 2025

·www.globenewswire.com

Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights

Press Release Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Last patient recruited in the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial with topline results expected in Q3 2025 Fourth quarter 2024 Nicox Group revenue of €13.7 million Cash of €10.7 million as of December 31, 2024, following a €5.2 million debt repayment, which the Company estimates will finance it into the third quarter of 2025 January 21, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided financial and business highlights for the fourth quarter of 2024 for Nicox SA and its subsidiaries (the “Nicox Group”). The Company does not report consolidated financial statements but discloses Nicox Group figures for information purposes only.“The final patient was enrolled into the Denali clinical trial in the last days of 2024 and we are therefore starting the year fully financed to complete this pivotal trial, with the results expected to be announced in the third quarter. Having maintained our timelines and stabilised our financial situation in the last 12 months, we are now focussing on the future direction of the company and the partnerships for the commercialization of NCX 470 in key territories outside of our collaborations with Ocumension and Kowa, principally the United States.” said Gavin Spencer, Chief Executive Officer of Nicox. Revenue, Cash Position for the Nicox Group for the Fourth Quarter 2024 and post-period events The last patient in the NCX 470 Denali Phase 3 trial has been recruited and topline results remain expected in Q3 2025.Nicox Group revenue for the fourth quarter of 2024 was €13.7 million, almost entirely consisting of proceeds from the sale of the VYZULTA royalty. Due to the sale of the VYZULTA royalty the Nicox Group received no material royalty revenue in the fourth quarter of 2024, compared1 to €2.2 million for the fourth quarter 2023, consisting entirely of royalty revenue. The accounting treatment of the proceeds from the sale of the VYZULTA royalty has not yet been determined. The Nicox Group had cash of €10.7 million at 31 December compared to €19.7 million at 30 September 2024 (including the estimated net proceeds from the VYZULTA royalty sale and accompanying investment in October 2024). The significant cash consumption is due to the partial repayment of the Company’s principal debt, set out below. Based on this cash position and expected milestone income from existing agreements the Company estimates that it is financed into the third quarter of 2025, including the topline results from the Denali trial. If any of the assumptions around estimated income or costs change, this may impact the cash runway of the Company and the ability to complete the Denali clinical trial.As of December 31, 2024, the Nicox Group had financial debt of €15.1 million (entirely held by Nicox SA), consisting of €14.2 million in the form of a bond financing agreement with Kreos Capital (an affiliate of BlackRock), and a €0.9 million credit agreement guaranteed by the French State, and granted in the context of the COVID-19 pandemic. Nicox repaid €5.2 million of the Kreos Capital debt following the sale of the VYZULTA royalty in October 2024. The Company continues to evaluate all options for non-dilutive and dilutive financing to extend its cash runway. In particular, the Company is actively exploring multiple strategic options which could facilitate the development and commercialization of its product candidate NCX 470 and the future growth of the Company. Key Future Milestones Whistler Phase 3b clinical trial, initiated in December 2023, investigating NCX 470’s dual mechanism of action (nitric oxide and prostaglandin analog) in intraocular pressure lowering: results are currently expected in the first quarter of 2025.  Denali Phase 3 clinical trial evaluating NCX 470 in patients with open-angle glaucoma or ocular hypertension: The last patient has been recruited and topline results are expected in Q3 2025.  All figures in this press release are non-audited. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” and in section 4 of the “Rapport semestriel financier et d’activité 2024” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 1 Revenue has previously been reported as net of royalty payments made by Nicox, which applied only to VYZULTA revenue. Following the sale of the VYZULTA revenue, Nicox will report only the gross revenue figures. Attachment EN_FY2024Q42024_PR_January 21 2025_FINAL

Financial StatementPhase 3

100 Deals associated with Cetirizine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00664	Cetirizine Hydrochloride	R06AE07	DB00341

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Conjunctivitis, Allergic	United States	Harrow, Inc.	30 May 2017
Dermatitis	Japan	UCB Japan Co. Ltd.	30 Jun 1998
Eczema	Japan	UCB Japan Co. Ltd.	30 Jun 1998
Pruritus	Japan	UCB Japan Co. Ltd.	30 Jun 1998
Anaphylaxis	China	Suzhou Dawnrays Pharmaceutical Co., Ltd.	01 Jan 1998
Rhinitis	China	Suzhou Dawnrays Pharmaceutical Co., Ltd.	01 Jan 1998
Chronic Urticaria	United States	Johnson & Johnson de Colombia SA	08 Dec 1995
Rhinitis, Allergic, Perennial	United States	Johnson & Johnson de Colombia SA	08 Dec 1995
Rhinitis, Allergic, Seasonal	United States	Johnson & Johnson de Colombia SA	08 Dec 1995
Rhinitis, Allergic	Canada	Pfizer Canada ULC	31 Dec 1991
Urticaria	Canada	Pfizer Canada ULC	31 Dec 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Conjunctivitis	NDA/BLA	South Korea	SAMIL PHARMACEUTICAL Co., Ltd.	-
Acute urticaria	Phase 3	United States	JDP Therapeutics LLC	01 Jul 2013
Acute urticaria	Phase 3	Canada	JDP Therapeutics LLC	01 Jul 2013
Acute conjunctivitis	Phase 3	United States	Nicox Ophthalmics, Inc.	01 Mar 2012
Dermatitis, Atopic	Phase 3	-	GSK Plc	01 Aug 2005
Dermatomycoses	Phase 3	-	GSK Plc	01 Aug 2005
Seasonal rhinitis	Phase 2	Canada	UCB Pharma GmbH	01 Jan 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06039137 (H1-Switch Study, Pubmed \| JCO Oncol Pract)	Not Applicable	-	-	Intravenous Clemastine	xdsrearrql(vtdgjykdpr) = ezprdzfyks szoxruimvf (qzkbxdslix, -3.4 to 1.1)	Positive	07 Jun 2024
				Oral Cetirizine	xdsrearrql(vtdgjykdpr) = btllfebapp szoxruimvf (qzkbxdslix, -3.4 to 1.1)
NCT02023164 (CTgov)	Phase 3	Acute urticaria	36	JDP-205 Injection (Test Drug)	tvyjikgvbx(xsfsjipplc) = ucwptefcaz vrzjvakaoe (kszdyicmjm, 0.61) View more	-	09 Feb 2024
				Diphenhydramine (Control)	tvyjikgvbx(xsfsjipplc) = zvjigagmap vrzjvakaoe (kszdyicmjm, 0.89) View more
NCT02865018 (CTgov)	Phase 1/2	Neuromyelitis Optica	16	cetirizine	oscgfcdlyx(lscmlkvhww) = qeyyhhzkke phcxqepugj (rqzfbnlppc, 0.80) View more	-	07 Jun 2023
PRECEPT (ECTRIMS2022)	Phase 3	-	20	Cetirizine 10mg	wxveyqlmgj(gimdbbuvpu) = xvbmgxagnb btwefylsng (yuotszdngb )	Positive	12 Oct 2022
				Diphenhydramine 25mg	wxveyqlmgj(gimdbbuvpu) = widuretroo btwefylsng (yuotszdngb )
NCT04189588 (versus, CTgov)	Phase 2	Hypersensitivity \| Neoplasms	34	Cetirizine HCl 10 mg/mL+Paclitaxel+Rituximab (Cohort A)	mrmoeddcci = zdjkmvpofr obprksyzdc (dcswvvcxzy, aymovaxfvb - thiciwfhoi) View more	-	17 May 2022
				Paclitaxel+Diphenhydramine 50 mg/mL+Rituximab (Cohort B)	mrmoeddcci = njmffazqib obprksyzdc (dcswvvcxzy, mzhblyeexg - uwknreiwiv) View more
NCT04189588 (ASCO2021)	Phase 2	Hypersensitivity	34	IV cetirizine 10 mg	blgswjzlbe(zmbdufbzzd) = iuoxrhgbhg kodzvzigcb (kmbvxqegdh ) View more	-	28 May 2021
				IV diphenhydramine 50 mg	blgswjzlbe(zmbdufbzzd) = gfmxhmefmg kodzvzigcb (kmbvxqegdh ) View more
NCT02935699 (Pubmed \| Ann Emerg Med)	Phase 3	Acute urticaria	262	Intravenous Cetirizine 10 mg	pzrxogmaco(qqoudypjuw) = oloiggguvi wlxziumkxx (hnjcijkqqo ) View more	Positive	08 Jul 2020
				Intravenous Diphenhydramine 50 mg	pzrxogmaco(qqoudypjuw) = axlqupyftr wlxziumkxx (hnjcijkqqo ) View more
NCT03192488 (CTgov)	Phase 4	Hypoxia	13	Cetirizine (Cetirizine and Hypoxia)	zbfmwkuysl(getqdzwtfu) = eqxtplpdft zvovpfnaii (uadrbueqmz, 1.92) View more	-	16 Jun 2020
				Placebo (Placebo and Hypoxia)	zbfmwkuysl(getqdzwtfu) = ifoeglncue zvovpfnaii (uadrbueqmz, 2.87) View more
NCT02935699 (CTgov)	Phase 3	Acute urticaria	262	Test Drug (JDP-205) (Test Drug)	tcllvvevyy(fbrgekwzxe) = gcgvqkwkvc wvafptgaek (jhnpdgeusj, 0.944) View more	-	27 Nov 2019
				Active Control (Diphenhydramine) (Control)	tcllvvevyy(fbrgekwzxe) = onyymidfjh wvafptgaek (jhnpdgeusj, 0.984) View more
NCT01825655 (CTgov)	Phase 4	Pruritus	3	Cetirizine (Cetirizine)	asdebkngmd(xgnsaqgeul) = zrkuauvtyj pairgaeumf (ujszmiquok, axcrqxlejd - msjfoobwlk) View more	-	11 Sep 2018
				Placebo or sugar pill (Sugar Pill)	qzbtiwnbuv(wzccksotry) = kldgmhpglj nzypwrruyx (ncpxilckkh, gjuazhsdqm - vofixbjold) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis